Published in Immunol Cell Biol on April 01, 2005
Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B (2007) 1.07
Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J Am Chem Soc (2012) 0.96
Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles. PLoS One (2014) 0.84
Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators. Vaccines (Basel) (2014) 0.84
Adjuvants for allergy vaccines. Hum Vaccin Immunother (2012) 0.82
Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One (2013) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
Tubular immunostimulating complex based on cucumarioside A2-2 and monogalactosyldiacylglycerol from marine macrophytes. J Nanobiotechnology (2011) 0.80
The Use of Synthetic Carriers in Malaria Vaccine Design. Vaccines (Basel) (2015) 0.80
Mucosal vaccination against tuberculosis using inert bioparticles. Infect Immun (2013) 0.79
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
In vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum. AAPS J (2009) 0.78
Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant. Curr Drug ther (2011) 0.78
Structure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle x-ray scattering. Biophys J (2012) 0.76
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing. Med Microbiol Immunol (2013) 0.75
The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iran J Basic Med Sci (2016) 0.75
Nanoparticulate Tubular Immunostimulating Complexes: Novel Formulation of Effective Adjuvants and Antigen Delivery Systems. Biomed Res Int (2017) 0.75
Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J (2010) 1.87
Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity (2009) 1.85
Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release (2011) 1.77
The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One (2011) 1.61
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 1.60
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice. Respir Res (2008) 1.46
Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS Pathog (2013) 1.39
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol (2008) 1.39
Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem (2007) 1.33
Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol (2002) 1.31
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol (2002) 1.12
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol (2013) 1.11
Influenza-induced inflammation drives pneumococcal otitis media. Infect Immun (2013) 1.11
Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol (2006) 1.09
A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol (2010) 1.02
Macrophages are mediators of gastritis in acute Helicobacter pylori infection in C57BL/6 mice. Infect Immun (2008) 1.01
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res (2004) 1.00
Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm (2012) 1.00
Q&A: What have we found out about the influenza A (H1N1) 2009 pandemic virus? J Biol (2009) 0.96
Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol (2006) 0.94
Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release (2012) 0.92
Abortive replication of influenza virus in mouse dendritic cells. J Virol (2012) 0.91
Pandemic vaccines: promises and pitfalls. Med J Aust (2006) 0.91
A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol (2010) 0.91
The source of the PB1 gene in influenza vaccine reassortants selectively alters the hemagglutinin content of the resulting seed virus. J Virol (2013) 0.88
The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol (2012) 0.87
Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza. Influenza Other Respir Viruses (2009) 0.87
Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine. Clin Vaccine Immunol (2011) 0.87
A mouse model for the study of contact-dependent transmission of influenza A virus and the factors that govern transmissibility. J Virol (2012) 0.86
Unlike CD4+ T-cell help, CD28 costimulation is necessary for effective primary CD8+ T-cell influenza-specific immunity. Eur J Immunol (2012) 0.85
Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine (2009) 0.85
Prevention and treatment of influenza with hyperimmune bovine colostrum antibody. PLoS One (2010) 0.84
Using bioluminescent imaging to investigate synergism between Streptococcus pneumoniae and influenza A virus in infant mice. J Vis Exp (2011) 0.84
Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine (2012) 0.83
Responses against complex antigens in various models of CD4 T-cell deficiency: surprises from an anti-CD4 antibody transgenic mouse. Immunol Res (2004) 0.83
Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine (2008) 0.83
Targeting CD45RB alters T cell migration and delays viral clearance. Int Immunol (2005) 0.83
CD8+ T cells are associated with severe gastritis in Helicobacter pylori-infected mice in the absence of CD4+ T cells. Infect Immun (2007) 0.82
Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation (2003) 0.82
A 320-kilobase artificial chromosome encoding the human HLA DR3-DQ2 MHC haplotype confers HLA restriction in transgenic mice. J Immunol (2002) 0.81
Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response. J Leukoc Biol (2012) 0.81
Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol (2003) 0.80
An insect antibacterial peptide-based drug delivery system. Mol Pharm (2005) 0.80
A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine (2008) 0.80
Serum amyloid P is a sialylated glycoprotein inhibitor of influenza A viruses. PLoS One (2013) 0.80
Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. J Control Release (2011) 0.79
The linear range for accurately quantifying antigen-specific T-cell frequencies by tetramer staining during natural immune responses. Eur J Immunol (2011) 0.79
Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Res (2012) 0.79
Immune responses in hepatitis C virus infection: the role of dendritic cells. Immunol Cell Biol (2003) 0.78
Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development. Expert Rev Respir Med (2009) 0.77
Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses. Vaccine (2004) 0.76
Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination. Vaccine (2008) 0.76
Considerations for the rapid deployment of vaccines against H7N9 influenza. Expert Rev Vaccines (2014) 0.76
ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza. Hum Vaccin Immunother (2015) 0.75
Impaired dendritic cell maturation in response to pandemic H1N109 influenza virus. J Clin Virol (2012) 0.75